Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study
Seigo Sugiyama, Akira Yoshida, Noboru Kurinami, Kunio Hieshima, Katsunori Jinnouchi, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Hideaki Jinnouchi · 2025
Read Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study by Seigo Sugiyama, Akira Yoshida, Noboru Kurinami, Kunio Hieshima, Katsunori Jinnouchi, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Hideaki Jinnouchi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12831498.txt.
Description
Seigo Sugiyama leads a team on a once a week diabetes drug. Their study from twenty twenty-five deals with semaglutide and blood vessel health. Folks with type two diabetes face high heart disease risk.
The team looked back at patients at a hospital in Japan. All had just started the once a week shot form. A wrist test checked how well vessel walls worked. Scores were taken before and after the drug began. Past work showed vessel health matters for heart risk. The team asks if this drug helps that score.
Catalog record
| CREATOR | Seigo Sugiyama, Akira Yoshida, Noboru Kurinami, Kunio Hieshima, Katsunori Jinnouchi, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Hideaki Jinnouchi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |